十月 2026
ijbs.com
显示 Similarweb 估计数据。
关联 GA4,公开验证您的网站指标
与您的成功同步
绑定 Google Analytics,验证您网站的流量及用户参与度指标
跳出率
47.17%
每次访问页数
2.13
平均访问时长
00:00:50
- 公司
- - -
- 行业
- - -
ijbs.com的 10 大竞争对手
在 十月 2026 与 ijbs.com 相似的前 10 名网站,按关键字流量、受众定位和市场重叠方面与 ijbs.com 的关联性排名
Nature is the foremost international weekly scientific journal in the world and is the flagship journal for Nature Portfolio. It publishes the finest ...
跳出率
55.37%
每次访问页数
2.51
平均访问时长
00:03:10
相似度评分
100%indexingmethod_automated - Search Results - PubMed
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
- -
每次访问页数
- -
平均访问时长
- -
sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
跳出率
31.28%
每次访问页数
6.01
平均访问时长
00:07:55
providing access to millions of research articles and chapters from science, technology and medicine, and humanities and social sciences
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
62.14%
每次访问页数
2.23
平均访问时长
00:03:01
Cerebrospinal fluid–venous fistula is an increasingly recognized cause of spontaneous intracranial hypotension.[1][1] The site of the leak is between the dural sleeve around a spinal nerve root and the surrounding foraminal veins. In appropriately investigated patients, transvenous embolization of the draining foraminal and paraspinal veins has been shown to be an effective way of treating the disease, with low periprocedural morbidity, improvement in symptoms and radiological appearances.[2][2] [Video 1][3] shows the technique employed in a typical case using Onyx (Medtronic, Minnesota, USA) to embolize a CSF–venous fistula at the right T10 neural foramen. Video 1 Video showing the technique for trans-venous embolization of a right T10 CSF-venous fistula for the treatment of spontaneous intracranial hypotension. The first section covers patient selection and work up, before then focusing on the technical aspects of navigating through the azygos system to the target foramen and completely occluding the pathway for CSF outflow. [1]: #ref-1 [2]: #ref-2 [3]: #F1
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
29.01%
每次访问页数
2.13
平均访问时长
00:00:59
Radioimmunotherapy using 225Ac, a highly cytotoxic α-particle emitter, has potential for treating advanced breast cancer, especially human epidermal growth factor receptor 2 (HER2)–positive cases. We use a pretargeted radioimmunotherapy (PRIT) approach consisting of a 3-step intravenous regimen (step 1: bispecific anti-HER2/anti-DOTA antibody; step 2: clearing agent; step 3: 225Ac-radiolabeled Proteus DOTA, or [225Ac]Ac-Pr). Our goal was to establish curative 225Ac-PRIT with high therapeutic indices. Methods: The impact of [225Ac]Ac-Pr specific activity was evaluated in the BT-474 breast xenograft model. We tested the effects of [225Ac]Ac-Pr dosing during PRIT on tumor-targeting efficiency and tissue biodistribution. Using a 225Ac-PRIT regimen consisting of a ratio of 1.19 nmol of bispecific antibody to 0.60–0.66 nmol of [225Ac]Ac-Pr, we evaluated therapy in the BT-474 model and a patient-derived xenograft model. BT-474-tumor–bearing mice were treated with 1 or 2 cycles of 225Ac-PRIT (37 kBq/cycle) separated by 1 wk. A dose escalation study was performed on the BT-474 model to establish an absorbed radiation dose of approximately 40 Gy (relative biological effectiveness [RBE], 5) as a nephrotoxic dose, as no such histologic findings were observed in prior studies at the 20.7-Gy (RBE, 5) renal dose level. Results: In the BT-474 model, 100% (20/20) achieved complete responses and histologic cure in 17 of 20 (85%) of the treated animals. One-cycle and 2-cycle treatments were equally effective. Treatments were well tolerated, with no chronic radiation toxicity documented during necropsy at 175 d. Dosimetry estimates (RBE, 5) per 37 kBq administered for tumors and kidneys were 210 and 3.5 Gy, respectively. In the patient-derived xenograft model, a single 225Ac-PRIT treatment led to 60% (3/5) complete response and prolonged survival (>93 d) versus no treatment (30 d; P = 0.0185). Lastly, a 225Ac-PRIT regimen was identified that induces severe chronic nephrotoxicity (41.4
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
56.36%
每次访问页数
2.04
平均访问时长
00:01:23
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
67.86%
每次访问页数
1.47
平均访问时长
00:00:06
Discover and read the most cited articles from BMJ Quality & Safety published over the past two years.
- 公司
- - -
- 行业
- - -
全球排名
- -
国家/地区排名
- -
品类排名
- -
跳出率
59.32%
每次访问页数
2.28
平均访问时长
00:01:19
Oncology On the Go With ASTCT Talks | Podcasts | CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
跳出率
45.98%
每次访问页数
1.59
平均访问时长
00:00:35
- 公司
- - -
- 行业
- - -
跳出率
52.85%
每次访问页数
1.56
平均访问时长
00:00:48
ijbs.com在 十月 2026 的前五名竞争对手是:nature.com、pubmed.ncbi.nlm.nih.gov、sciencedirect.com、link.springer.com等。
根据 Similarweb 的月访问量数据,ijbs.com 在 十月 2026 的头号竞争对手是 nature.com。与 ijbs.com 相似度排名第二的网站是 pubmed.ncbi.nlm.nih.gov,排名第三的是 sciencedirect.com。
在 十月 2026,link.springer.com 被评为与 ijbs.com 相似度第四高的网站,jnis.bmj.com 位居第五。
进入前十名榜单的其他五家竞争对手分别是 jnm.snmjournals.org、n.neurology.org、qualitysafety.bmj.com、cancernetwork.com 和 contemporaryobgyn.net。
